Summary
Cardiome Pharma Corp (Cardiome), is a specialty pharmaceutical company, which develops and commercializes therapies for the treatment and prevention of cardiovascular diseases. The company’s product portfolio includes two marketed products: Brinavess, for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults; and Aggrastat, a GP IIb/IIIa inhibitor used for the treatment of acute coronary syndrome (ACS). Its pipeline product includes Trevyent, which is a drug device combination under development for Pulmonary Arterial Hypertension (PAH). Cardiome has collaborations with other pharmaceutical companies to commercialize Brinavess. It has operational presence with offices located in Canada, the US, Switzerland and the UK. Cardiome is headquartered in Vancouver, British Columbia, Canada.
Cardiome Pharma Corp (COM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Cardiome Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cardiome Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cardiome Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cardiome Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Cardiome Pharma Corp, Medical Devices Deals, 2011 to YTD 2017 11
Cardiome Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Cardiome Pharma Corp, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
Cardiome Pharma Enters into Agreement with Chong Kun Dang for BRINAVESS 14
Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 14
Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma 15
Cardiome Pharma Enters into Agreement with Eddingpharm to Develop and Commercialize Brinavess 16
Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 17
Correvio International Enters into Distribution Agreement with Eurolab Especialidades for Brinavess 18
Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma for Aggrastat 19
Cardiome Pharma Enters Into Commercialization Agreement With UDG Healthcare For Brinavess In Ireland 19
Cardiome Enters Into Commercialization Agreement With Algorithm For Brinavess 20
Cardiome Pharma Enters Into Commercialization Agreement With Tzamal Medical For Brinavess 21
Cardiome Pharma Enters Into Commercialization Agreement With AOP Orphan Pharma For Brinavess 22
Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 23
Licensing Agreements 24
Tzamal Medical Enters into Licensing Agreement with Cardiome Pharma 24
SteadyMed Enters into Licensing Agreement with Cardiome Pharma 25
Medicure International Enters Into Licensing Agreement With Iroko Cardio For AGGRASTAT 26
Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 26
Eddingpharm Enters into Licensing Agreement with Correvio International 27
Equity Offering 28
Cardiome Pharma Raises USD34.5 Million in Public Offering of Shares 28
Cardiome Pharma to Raise up to USD20 Million in Private Placement of Shares 30
Cardiome Pharma Raises USD23 Million in Public Offering of Shares 31
Cardiome Pharma Completes Public Offering Of Shares For Us$13.7 Million 32
Acquisition 34
Cardiome Pharma Acquires Correvio, Cardiovascular Products Provider 34
CarCor Investment Acquires 16.6% Stake In Cardiome Pharma 35
Cardiome Pharma Corp - Key Competitors 37
Key Employees 38
Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
May 15, 2017: Cardiome Reports First Quarter 2017 Financial Results 40
Mar 07, 2017: Cardiome Reports Fourth Quarter and Full Year 2016 Financial Results 41
Nov 07, 2016: Cardiome Reports Third Quarter 2016 Financial Results 43
Aug 09, 2016: Cardiome Reports Second Quarter 2016 Financial Results 45
May 13, 2016: Cardiome Reports First Quarter 2016 Financial Results 47
Mar 10, 2016: Cardiome Reports Fourth Quarter and Full Year 2015 Financial Results 48
Corporate Communications 50
May 16, 2017: Cardiome Reports Changes To Senior Management Team 50
Legal and Regulatory 51
Feb 19, 2016: Cardiome announces filing of shelf prospectus and registration statement 51
Other Significant Developments 52
Oct 14, 2016: Cardiome Announces Initiation of Commercial Operations in Canada, Eh 52
Jun 14, 2016: Cardiome Announces Term Loan Agreement with CRG 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54
List of Tables
Cardiome Pharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Cardiome Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cardiome Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cardiome Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cardiome Pharma Corp, Deals By Therapy Area, 2011 to YTD 2017 9
Cardiome Pharma Corp, Medical Devices Deals, 2011 to YTD 2017 11
Cardiome Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Cardiome Pharma Enters into Agreement with Chong Kun Dang for BRINAVESS 14
Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 14
Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma 15
Cardiome Pharma Enters into Agreement with Eddingpharm to Develop and Commercialize Brinavess 16
Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 17
Correvio International Enters into Distribution Agreement with Eurolab Especialidades for Brinavess 18
Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma for Aggrastat 19
Cardiome Pharma Enters Into Commercialization Agreement With UDG Healthcare For Brinavess In Ireland 19
Cardiome Enters Into Commercialization Agreement With Algorithm For Brinavess 20
Cardiome Pharma Enters Into Commercialization Agreement With Tzamal Medical For Brinavess 21
Cardiome Pharma Enters Into Commercialization Agreement With AOP Orphan Pharma For Brinavess 22
Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 23
Tzamal Medical Enters into Licensing Agreement with Cardiome Pharma 24
SteadyMed Enters into Licensing Agreement with Cardiome Pharma 25
Medicure International Enters Into Licensing Agreement With Iroko Cardio For AGGRASTAT 26
Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 26
Eddingpharm Enters into Licensing Agreement with Correvio International 27
Cardiome Pharma Raises USD34.5 Million in Public Offering of Shares 28
Cardiome Pharma to Raise up to USD20 Million in Private Placement of Shares 30
Cardiome Pharma Raises USD23 Million in Public Offering of Shares 31
Cardiome Pharma Completes Public Offering Of Shares For Us$13.7 Million 32
Cardiome Pharma Acquires Correvio, Cardiovascular Products Provider 34
CarCor Investment Acquires 16.6% Stake In Cardiome Pharma 35
Cardiome Pharma Corp, Key Competitors 37
Cardiome Pharma Corp, Key Employees 38
Cardiome Pharma Corp, Subsidiaries 39List of Figures
Cardiome Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Cardiome Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Cardiome Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Cardiome Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Cardiome Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cardiome Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Cardiome Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cardiome Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Cardiome Pharma Corp, Medical Devices Deals, 2011 to YTD 2017 11
